ImmunoScape inks agreement with Cue Biopharma to launch next-gen cancer immunotherapy
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Acquisition expands Merck’s growing hematology portfolio
Subscribe To Our Newsletter & Stay Updated